INTRODUCTION AND OBJECTIVES: The prostate health index (PHI) is superior to PSA and other PSA-derivatives for the detection of prostate cancer (PCa). We sought to explore the utility of PHI density for the detection of clinically-significant PCa in a contemporary cohort of men presenting for diagnostic workup of PCa.
INTRODUCTION AND OBJECTIVES: Current prognostic classification of prostate cancer (PCa) is based on Gleason scoring, which is subjective & lacks precision. We sought to identify discriminant methylated DNA markers with potential to enhance prognostic assessment.
METHODS: For discovery, whole methylome sequencing was applied to DNA extracted from 54 frozen archival tissues [36 PCa cases (18 Gleason 3+3, 18 Gleason 7) and 18 normal-appearing prostate controls]. For tissue validation, top candidate markers were assayed by methylation-specific PCR on an independent set of 50 case and 35 control tissues. Tissues were obtained from radical prostatectomies done between 2003-2007; all were reviewed pathologically and microdissected prior to DNA extraction and bisulfite treatment. Marker levels were standardized to total human DNA. From the discovery set, marker distributions in cases and controls were assessed to identify discriminant candidates. Markers were correlated with progression (PSA >0.4 ng/ml or confirmed recurrence) using regression partitioning trees (rPart) in PCa cases. From the rPart model, subjects were categorized as low, medium, and high risk progression groups. The prognostic value of methylation markers relative to Gleason scoring was assessed with the likelihood ratio test of competing cox proportional hazards models.
RESULTS: In the discovery set, 120 candidate markers exceeded filtering criteria (AUC>0.95, fold-change >10, p<0.005). Of these, the top 72 candidate markers were evaluated in the independent set. Numerous markers were identified that highly discriminated PCa from normal-appearing prostate controls, with some achieving AUCs > 0.99. Five prognostic markers (FAM78A, WNT3A, GAS6, LOC100129726, and MAXchr727) were selected by the rPart modeling. The risk grouping defined by methylated DNA markers added significant prognostic content in predicting progression-free survival relative to Gleason scoring (p<0.0001) whereas Gleason scoring had no added value relative to methylated DNA marker risk grouping (p¼0.43) ( figure) CONCLUSIONS: Based on these discovery and early validation data, we identify novel methylated DNA markers with potential to accurately predict progression in PCa. Further exploration is clearly warranted to corroborate and extend these intriguing findings. 
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INTRODUCTION AND OBJECTIVES:
The 4Kscore test was previously validated in a large, prospective trial to predict aggressive prostate cancer, however, the study population had a limited number of African American (AA) men. We conducted an independent multi-institutional, prospective trial to validate the 4Kscore test within the Veterans Affairs (VA) Health System, where a large proportion of the men getting care are AA.
METHODS: We prospectively enrolled men who were referred for biopsy of their prostate at 8 diverse VA sites throughout the nation. All men underwent phlebotomy for 4Kscore ascertainment prior to prostate biopsy. We assessed the discrimination, calibration, and clinical utility of the 4Kscore test for predicting Gleason 7 or higher (G7+) e1356
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